NASDAQ$NTRA
Natera Inc · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
Reported strong momentum driven by record volume levels, leading to raised 2022 revenue guidance.
Natera reported a 39.6% increase in total revenues, reaching $198.2 million in Q2 2022 compared to $142.0 million in Q2 2021. The company processed approximately 499,900 tests, including 484,000 accessioned in its laboratory. They are expecting to reach a cash flow breakeven quarter by mid-2024.
- Total revenues increased by 39.6% to $198.2 million compared to Q2 2021.
- Product revenues increased by 39.3% to $194.6 million compared to Q2 2021.
- Natera processed approximately 499,900 tests, including approximately 484,000 tests accessioned in its laboratory.
- Medicare coverage received for Signatera in muscle-invasive bladder cancer.
Headline financials
Revenue & EPS history
Natera · Revenue · Quarterly
$198M
Revenue by segment
Natera · $33.9M total across 1 segment · Q1 2021
- Licensing and other revenues$33.9M—100.0%
Forward guidance
Natera anticipates 2022 total revenue of $805 million to $825 million; 2022 gross margin to be approximately 46% to 48% of revenues; selling, general and administrative costs to be approximately $560 million to $590 million; research and development costs to be $340 million to $360 million, and net cash consumption to be $370 million to $400 million.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2022
+4.4%
Avg return
Earnings day
+4.4%
Avg return
5 days after
+6.0%
Avg return
30 days after
69%
31 / 45 earnings
Positive
+29.1%
Q2 2017
Best reaction
-21.2%
Q3 2018
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.0% | -5.2% | +0.0% | |
| Q4 2025 | -3.8% | -6.0% | -15.5% | |
| Q3 2025 | +0.7% | +5.6% | +23.2% | |
| Q1 2025 | -6.9% | -6.9% | +0.7% | |
| Q4 2024 | -0.7% | -5.5% | -8.1% | |
| Q3 2024 | +20.2% | +9.0% | +24.2% | |
| Q2 2024 | +14.2% | +18.6% | +12.5% | |
| Q1 2024 | +10.1% | +10.3% | +16.2% | |
| Q4 2023 | +13.6% | +18.4% | +20.1% | |
| Q3 2023 | +4.0% | +11.2% | +33.2% | |
| Q2 2023 | +16.1% | +20.0% | +42.3% | |
| Q1 2023 | -3.6% | -3.8% | -8.1% | |
| Q4 2022 | +14.1% | +22.2% | +14.1% | |
| Q3 2022 | -13.2% | -5.3% | -9.2% | |
| Q2 2022 | +5.1% | +3.7% | -2.7% | |
| Q1 2022 | -2.0% | -18.5% | +0.5% | |
| Q4 2021 | +10.2% | +5.9% | -34.7% | |
| Q3 2021 | +3.6% | +1.2% | -22.7% | |
| Q2 2021 | +2.4% | -7.7% | +8.1% | |
| Q1 2021 | -2.9% | -14.0% | -7.1% | |
| Q4 2020 | +2.9% | +4.6% | -17.0% | |
| Q3 2020 | +9.3% | +2.3% | +16.5% | |
| Q2 2020 | +11.8% | +4.0% | +31.2% | |
| Q1 2020 | +19.8% | +28.3% | +11.6% | |
| Q4 2019 | +6.4% | +5.6% | -27.3% | |
| Q3 2019 | -3.7% | +0.3% | -1.3% | |
| Q2 2019 | +19.3% | +9.6% | +19.8% | |
| Q1 2019 | +19.8% | +26.8% | +34.3% | |
| Q4 2018 | +19.6% | +16.9% | +22.9% | |
| Q3 2018 | -21.2% | -25.2% | -20.4% | |
| Q2 2018 | +0.2% | +5.2% | +8.4% | |
| Q1 2018 | +1.4% | -0.9% | +3.6% | |
| Q4 2017 | +0.3% | +17.3% | +10.1% | |
| Q3 2017 | -12.8% | -13.4% | -11.9% | |
| Q2 2017 | +29.1% | +32.4% | +64.0% | |
| Q1 2017 | +13.8% | +11.5% | +7.1% | |
| Q4 2016 | -14.8% | -15.9% | -10.8% | |
| Q3 2016 | +12.0% | +25.5% | +26.8% | |
| Q2 2016 | -5.8% | -17.2% | -21.3% | |
| Q1 2016 | +15.4% | — | — | |
| Q1 2014 | +0.1% | — | — | |
| Q4 2015 | -13.8% | — | — | |
| Q3 2014 | +2.7% | — | — | |
| Q3 2015 | +7.0% | — | — | |
| Q2 2014 | -3.6% | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q1 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro